Stock Watch: Unnatural Selection In Clinical Trials
Have We Been Doing It Wrong All These Years?
Patient selection is held out as the Achilles heel of clinical trial success. But a surprise and fortunate finding in Pfizer’s gene therapy trial has already resulted in tightened recruitment criteria, thanks to genetic analysis.
You may also be interested in...
Some commercial-stage biotechnology companies blame the pandemic for their declining sales and continued losses. While an acquisition by a bigger company might once have been an aspiration, further fundraisings seem to be the more likely outcome.
Another blow-out quarter from Pfizer provided the impetus for an acquisition. But the history of recent commercial-stage biotech transactions and the risky nature of all early-stage companies suggest that the floodgates will not burst open.
A post-pandemic rebound in oncology sales contrasts with the lagging revenues of drugs administered by primary care and office-based specialists. Declining COVID-19 vaccine, diagnostic and treatment revenues could add further volatility.